-1 	|BT| (NP (NP (JJ Protective) (NN effect) (NN dioscin) (JJ alcohol-induced) (NN liver) (NN injury))) |ET| |BS|242:A03.620 751:D02.033.375 822:D02.033|ES| 19:1 75:1 836:1 2416:1 2672:1 2909:1 2910:1

-1 	|BT| (NP (NP (NN Protein) (NN kinase) (JJ potential) (JJ chemotherapeutic) (NN target) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 151:E02.319 823:D08.811.913.696.620.682.700.150.125|ES| 17:1 18:1 19:1 160:1 470:1 827:1 1762:1 2911:1

-1 	|BT| (S (NP (NN Pterostilbene)) (VP (VBZ inhibits) (NP (NP (NP (JJ colorectal) (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN ACF)) (-RRB- -RRB-))) (NP (NP (NN colon) (NN carcinogenesis)) (PP (IN via) (NP (NN suppression) (JJ multiple) (NN signal) (NN transduction) (NN pathway) (JJ azoxymethane-treated) (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 52:E02 122:C14.280.383 126:G02.111.087.800 132:D02.172.080 824:C04.834.020|ES| 10:1 14:1 17:1 19:1 52:1 113:1 207:1 383:1 596:1 615:1 649:1 859:1 1431:1 1725:1 2453:1 2793:1 2912:1 2913:1 2914:1 2915:1

-1 	|BT| (S (NP (NN PURPOSE) (: :)) (NP (DT The) (JJ objective)) (VP (VBP investigate) (SBAR (IN whether) (S (NP (NP (NN polymorphism) (JJ putative) (NN influence) (NN fluorouracil/oxaliplatin) (NN activity)) (VBN associated) (JJ clinical) (NN outcome) (NN patient)) (VP (VBD advanced) (NP (NP (JJ colorectal) (NN cancer)) (VP (VBN treated) (NP (NP (JJ first-line) (NN oxaliplatin)) (, ,) (NP (JJ folinic) (NN acid)) (, ,) (NP (NN fluorouracil) (JJ palliative) (NN chemotherapy)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 52:E02 151:E02.319 307:G05.365.795 415:F01.658.500 560:D03.383.742.698.875.404 825:D03.438.733.631.400.800.350.450 826:F01.752.609|ES| 2:1 17:1 18:1 19:1 84:1 104:1 120:1 169:1 221:1 399:1 459:1 495:1 547:1 687:1 691:1 867:1 918:1 997:1 1060:1 1099:1 1275:1 2490:1 2543:1 2916:1 2917:1 2918:1 2919:1 2920:1

-1 	|BT| (NP (NP (NP (NN Ras) (NN pathway) (NN activation) (JJ hepatocellular) (NN carcinoma) (JJ anti-tumoral) (NN effect)) (NP (VBN combined) (JJ sorafenib) (NN rapamycin) (FW vivo)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 104:C04.557.470.200.025.255 827:D02.540.505.760|ES| 19:1 75:1 164:1 225:1 303:1 304:1 378:1 383:1 1775:1 2063:1 2921:1 2922:1

-1 	|BT| (S (S (NP (JJ Regular) (NN aspirin) (NN use) (NN diagnosis)) (VP (VBD associated) (NP (JJR lower) (NN risk) (JJ colorectal) (JJ cancer-specific) (NN mortality)) (PP (IN among) (NP (NP (NN participant) (JJ primary) (NN tumor) (JJ overexpressed) (NN COX-2)) (PRN (-LRB- -LRB-) (NP (NP (JJ multivariate) (NN HR)) (, ,) (NP (CD 0.39)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD 0.20-0.76)))) (-RRB- -RRB-)))))) (, ,) (IN whereas) (S (NP (NN aspirin) (NN use)) (VP (VBD associated) (NP (JJR lower) (NN risk)) (PP (IN among) (NP (NP (JJ primary) (NN tumor) (JJ weak) (JJ absent) (NN expression)) (PRN (-LRB- -LRB-) (NP (NP (JJ multivariate) (NN HR)) (, ,) (NP (CD 1.22)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD 0.36-4.18)))) (-RRB- -RRB-))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 61:E05.318.740.600.800 263:E01 670:D02.455.426.559.389.657.410.595.176 695:E05.318.308.985.550 828:Z01.107.757.235|ES| 2:1 7:1 10:1 14:1 17:1 19:1 25:1 76:1 115:1 117:1 169:1 171:1 217:1 338:1 344:1 367:1 369:1 372:1 374:1 1037:1 1372:1 1659:1 2487:1 2508:1 2509:1 2511:1 2923:1 2924:1 2925:1 2926:1 2927:1 2928:1 2929:1 2930:1

-1 	|BT| (S (NP (NNS Results)) (NP (ADJP (FW vitro) (FW vivo)) (NN bioassay)) (ADVP (RB clearly)) (VP (VBP suggest) (SBAR (S (NP (NN beta-ionone)) (VP (MD could) (VP (VBD developed) (NP (NN prevention) (NN treatment) (NN colon) (NN cancer)))))))) |ET| |BS|52:E02 106:E05.091|ES| 18:1 19:1 113:1 216:1 378:1 546:1 702:1 796:1 908:1 1165:1 1474:1 2838:1 2931:1 2932:1

-1 	|BT| (FRAG (NP (NNS RESULTS)) (: :) (NP (NP (NN Liver) (NN tumor) (NN mass)) (NP (NP (NP (JJR lower) (NN pravastatin) (NN group)) (PRN (-LRB- -LRB-) (NP (NN PG)) (-RRB- -RRB-))) (NP (NP (NP (NN control) (NN group)) (PRN (-LRB- -LRB-) (NP (NN CG)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN estimated) (NN number) (NN liver) (NN tumor)) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (ADJP (JJR <) (NP (CD 0.004)))) (-RRB- -RRB-))) (NP (NP (NN liver) (NN weight/body) (NN weight) (NN ratio)) (PRN (-LRB- -LRB-) (S (NP (NN p)) (NP (QP (JJR <) (CD 0.04)))) (-RRB- -RRB-))))))) |ET| |BS|242:A03.620 515:C04.588.274.623 616:E05.318.780.074 653:C23.888.144 817:D02.455.426.559.847.638.930 829:M01.686|ES| 2:1 7:1 10:1 14:1 19:1 104:1 117:1 289:1 312:1 646:1 710:1 836:1 2300:1 2399:1 2721:1 2804:1 2933:1 2934:1 2935:1 2936:1 2937:1 2938:1 2939:1 2940:1 2941:1

-1 	|BT| (S (NP (NNS RESULTS) (: :)) (NP (NN Silibinin) (NN feeding)) (VP (VBD showed) (NP (NP (ADJP (NP (JJ dose-dependent) (NN decrease) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis)) (JJR stronger)) (NN efficacy) (NN pretreatment)) (CC versus) (NP (NN posttreatment) (NNS regimen))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 532:E02.183|ES| 19:1 78:1 104:1 113:1 132:1 295:1 710:1 1881:1 1983:1 2304:1 2531:1 2533:1 2824:1 2942:1 2943:1 2944:1 2945:1

-1 	|BT| (S (NP (NNP Resveratrol)) (VP (VBZ interferes) (NP (NP (JJ N-nitrosodiethylamine-induced) (JJ hepatocellular) (NN carcinoma)) (JJ early) (JJ advanced) (NN stage) (JJ male) (JJ Wistar) (NN rat)))) |ET| |BS|104:C04.557.470.200.025.255 554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900|ES| 19:1 303:1 304:1 849:1 997:1 1128:1 1129:1 1402:1 2603:1 2946:1 2947:1 2948:1

-1 	|BT| (S (S (NP (NN Rimonabant)) (VP (VBZ inhibits) (NP (JJ human) (NN colon) (NN cancer) (NN cell) (NN growth)))) (VP (VBZ reduces) (NP (NN formation) (JJ precancerous) (NN lesion) (NN mouse) (NN colon)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 20:G03.495 41:A11 45:G07.700.320.249 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 122:C14.280.383 341:C04.834|ES| 18:1 19:1 36:1 43:1 52:1 94:1 102:1 113:1 142:1 615:1 1130:1 1131:1 2949:1

-1 	|BT| (NP (NP (NN Role) (NN Fas/FasL) (NN pathway) (NN combination) (NN therapy) (NN interferon-alpha) (NN fluorouracil) (JJ hepatocellular) (NN carcinoma) (NN vitro))) |ET| |BS|15:F01.829.316.616 104:C04.557.470.200.025.255 356:D12.644.276.374.440.890.250 560:D03.383.742.698.875.404 618:E02.186|ES| 19:1 130:1 216:1 303:1 304:1 383:1 530:1 1198:1 2187:1 2919:1 2950:1

-1 	|BT| (NP (NP (NNP Saffron)) (: :) (NP (JJ potential) (NN candidate) (JJ novel) (JJ anticancer) (NN drug) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|67:D26 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500 701:B01.650.940.800.575.100.549.500|ES| 19:1 104:1 191:1 303:1 304:1 827:1 891:1 1243:1 1880:1 2951:1

-1 	|BT| (NP (NP (NNP Sesamin)) (, ,) (NP (JJ lipid-soluble) (NN lignan)) (, ,) (S (NP (CD one) (NN agent)) (VP (VBZ belongs) (NP (SBAR (S (NP (NP (NN class) (NNS phytoestrogens)) (, ,) (NP (NP (VBN isolated) (NN sesame)) (PRN (-LRB- -LRB-) (NP (NN Sesamum) (NN indicum)) (-RRB- -RRB-))) (, ,)) (VP (VBN linked) (NP (NN prevention) (NN hyperlipidemia))))) (, ,) (NP (NP (NN hypertension)) (, ,) (NP (NN carcinogenesis) (JJ unknown) (NN mechanism))))))) |ET| |BS|33:C04.697.098 621:D02.455.426.559.389.140.450 659:D10 766:C18.452.584.500.500 830:B01.650.940.800.575.100.583.690.750 831:D27.505.696.399.472.277.540.500 832:C14.907.489|ES| 2:1 10:1 14:1 19:1 162:1 207:1 728:1 1010:1 1363:1 1474:1 1653:1 2182:1 2313:1 2692:1 2814:1 2952:1 2953:1 2954:1 2955:1 2956:1 2957:1 2958:1 2959:1

-1 	|BT| (NP (NP (NN Signal) (NN transducer) (NN activator) (NN transcription) (CD 3) (JJ molecular) (NN therapy) (JJ non-small-cell) (NN lung) (NN cancer))) |ET| |BS|52:E02 110:C04.588.894.797.520.109.220.249 209:G02.111.087.847 250:E07.305.812 375:Z01.639.100|ES| 18:1 19:1 130:1 161:1 327:1 328:1 487:1 860:1 861:1 862:1 2960:1

-1 	|BT| (S (NP (NN Simvastatin)) (VP (VP (VBZ induces) (NP (NN apoptosis) (JJ human) (NN colon) (NN cancer) (NN cell) (NN tumor) (NN xenograft))) (, ,) (VP (VBZ attenuates) (NP (JJ colitis-associated) (NN colon) (NN cancer) (NN mouse))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 41:A11 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 92:E04.936.764 93:A01.941.875 754:D02.455.426.559.847.638.400.900|ES| 2:1 7:1 18:1 19:1 36:1 52:1 89:1 94:1 113:1 214:1 265:1 410:1 2423:1 2961:1

-1 	|BT| (S (NP (NN Sodium) (NN alginate)) (VP (VBZ prevents) (NP (NN progression) (JJ non-alcoholic) (NN steatohepatitis) (NN liver) (NN carcinogenesis) (JJ obese) (JJ diabetic) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 33:C04.697.098 242:A03.620 509:C06.552.241.519 564:C18.654.726.500|ES| 19:1 48:1 52:1 207:1 836:1 1791:1 2069:1 2468:1 2718:1 2962:1 2963:1 2964:1

-1 	|BT| (S (NP (NN Sulindac) (NNS NSAIDs)) (VP (ADVP (RB widely)) (NP (VBN studied) (NP (JJ potential) (JJ chemopreventive) (NN agent) (NN colon) (NN cancer))))) |ET| |BS|251:D02.455.426.559.847.486.875 796:D27.505.696.663.850.014.040.500 833:D27.505.696.706.018|ES| 18:1 19:1 113:1 401:1 728:1 827:1 1946:1 2369:1 2965:1 2966:1

-1 	|BT| (S (NP (NP (NN Supplementation) (JJ branched-chain) (NN amino) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN BCAA)) (-RRB- -RRB-))) (VP (VBZ reduces) (NP (NP (NN risk) (NN liver) (NN cancer) (JJ cirrhotic) (NN patient)) (NP (JJ obese) (, ,) (NP (JJ associated) (NN improvement) (NN insulin) (NN resistance)))))) |ET| |BS|50:M01.643 61:E05.318.740.600.800 564:C18.654.726.500 639:D12.125.070 678:C18.452.394.968.500|ES| 2:1 10:1 14:1 18:1 19:1 120:1 142:1 169:1 171:1 836:1 1094:1 1275:1 2189:1 2359:1 2360:1 2364:1 2468:1 2967:1 2968:1 2969:1

-1 	|BT| (S (NP (NP (NP (NN Suppression) (JJ early) (NN stage) (JJ neoplastic) (NN transformation)) (JJ two-stage) (NN chemical) (NN hepatocarcinogenesis) (NN model)) (: :) (S (NP (NP (NN supplementation) (NN vanadium)) (, ,) (NP (JJ dietary) (NN micronutrient)) (, ,) (NP (NN limit) (NN cell) (NN proliferation))) (VP (VBZ inhibits) (NP (NP (NN formation) (NN 8-hydroxy-2)) ('' ')))) (: -)) (VP (NNS deoxyguanosines) (NP (NN DNA) (NNS strand-breaks) (NN liver) (JJ sprague-dawley) (NN rat)))) |ET| |BS|20:G03.495 32:C04.697.098.500 122:C14.280.383 183:G04.299.233.750 242:A03.620 595:G07.203.650.240 769:B01.050.150.900.649.865.635.505.700.750 834:D27.505.696.377.605.555 835:D27.505.696.377.605 836:G05.355.180.210 837:D01.268.556.920 838:E05.599.495|ES| 2:1 19:1 43:1 72:1 94:1 104:1 299:1 615:1 666:1 836:1 849:1 893:1 900:1 1128:1 1129:1 1384:1 2124:1 2567:1 2594:1 2797:1 2970:1 2971:1 2972:1 2973:1 2974:1 2975:1 2976:1

-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (SBAR (S (NP (NP (VBN indicated) (NN nifuroxazide)) (VP (MD could) (VP (ADVP (RB effectively)) (VB inhibit) (NP (NN tumor) (NN metastasis)) (S (VP (VBG mediating) (NP (NP (NN Stat3)) (NN pathway))))))) (VP (MD might) (NP (JJ therapeutic) (JJ potential) (NN treatment) (NN CRC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 52:E02 82:D12.644.360.024.342.300 113:C04.697.650 122:C14.280.383|ES| 2:1 7:1 19:1 101:1 245:1 383:1 541:1 546:1 761:1 798:1 806:1 827:1 908:1 1370:1 1537:1 1538:1 1541:1 2646:1 2820:1 2977:1

-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP provide) (SBAR (S (NP (NP (NN evidence) (NN plant) (NN flavonoid) (NN fisetin)) (VP (VBP induce) (NP (NN apoptosis)))) (VP (VBP suppress) (NP (NP (NN growth) (NN colon) (NN cancer) (NN cell) (NN inhibition) (NN COX2)) (: -) (NP (NN Wnt/EGFR/NF-kappaB-signaling) (NN pathway)))))))) |ET| |BS|38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 41:A11 43:F01.145.544 45:G07.700.320.249 147:G02.149.115.800.925 210:D12.776.260.600 328:B01.650 534:D03.383.663.283.266.450|ES| 2:1 18:1 19:1 38:1 89:1 94:1 102:1 103:1 113:1 243:1 383:1 711:1 1098:1 1537:1 1538:1 1886:1 2441:1 2978:1 2979:1 2980:1

-1 	|BT| (S (NP (VBN Targeted) (NN disruption) (JJ Nemo-like) (NN kinase)) (VP (VBZ inhibits) (NP (NN tumor) (NN cell) (NN growth) (JJ simultaneous) (NN suppression) (NN cyclin) (NN D1) (NN CDK2) (JJ human) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|8:C04 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 122:C14.280.383 215:D12.644.360.262.150.100 469:D08.811.913.696|ES| 7:1 19:1 36:1 94:1 102:1 303:1 304:1 470:1 615:1 743:1 744:1 1602:1 2453:1 2981:1 2982:1 2983:1 2984:1

-1 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBP investigate) (NP (NP (NP (NP (JJ molecular) (NN mechanism) (JJ chemopreventive) (NN effect)) (JJ folic) (NN acid) (NN tributyrin)) (ADVP (RB alone))) (NN combination) (NN rat) (NN hepatocarcinogenesis)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 624:D27.505.696.706.018 839:D03.438.733.631.400|ES| 19:1 75:1 131:1 161:1 162:1 241:1 459:1 530:1 691:1 849:1 900:1 1275:1 1567:1 1946:1 2985:1 2986:1

-1 	|BT| (S (NP (DT The) (NN cyclooxygenase-2) (-LRB- -LRB-) (NN COX-2) (-RRB- -RRB-) (NN inhibitor) (NN celecoxib)) (VP (VBN approved) (NP (NP (NN drug) (NN clinic) (NN colon) (NN cancer) (NN chemoprevention)) (VP (VBN tested) (NP (NP (JJ chemopreventive) (JJ therapeutic) (NN efficacy)) (JJ various) (JJ clinical) (NN trial)))))) |ET| |BS|12:Z01.542.049 52:E02 67:D26 253:E02.319.162 349:D27.505.519.389.310.500 683:D27.505.519.389.310 684:D02.065.884.247 840:E01.789.800 841:E05.318.760.250.500 842:N02.278.035|ES| 10:1 14:1 18:1 19:1 61:1 76:1 84:1 113:1 191:1 380:1 541:1 691:1 870:1 1096:1 1946:1 2304:1 2343:1 2807:1 2987:1 2988:1 2989:1

-1 	|BT| (S (NP (DT The) (NNS data)) (VP (VBP provide) (NP (JJ additional) (NN evidence) (JJ potential) (NN use) (NN roxithromycin) (NN treatment) (JJ hepatocellular) (NN carcinoma) (NN prevention)))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 843:D02.540.576.500.992.630|ES| 19:1 38:1 303:1 304:1 546:1 691:1 711:1 793:1 827:1 980:1 1474:1 1659:1 2990:1

-1 	|BT| (NP (NP (NP (DT The) (JJ Dual) (NN Inhibition) (NN RNA) (NN Pol)) (SBAR (S (NP (PRP I)) (NP (NN Transcription) (NNP PIM) (NN Kinase) (NNP New) (JJ Therapeutic) (NNP Approach) (NNP Treat) (NNP Advanced) (NNP Prostate) (NNP Cancer)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 52:E02 209:G02.111.087.847 844:D08.811.913.696.445.735.270.750|ES| 19:1 469:1 515:1 691:1 1197:1 1412:1 1919:1 2280:1 2350:1 2703:1 2991:1 2992:1 2993:1 2994:1 2995:1 2996:1 2997:1

-1 	|BT| (S (NP (DT The) (JJ oncogenic) (NN kinase) (NN inhibitor) (NN sorafenib)) (ADVP (RB significantly)) (VP (VB prolong) (SBAR (S (NP (JJ median) (NN survival) (NN patient)) (VP (VBD advanced) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (, ,) (SBAR (IN although) (S (NP (NN response) (JJ disease-stabilizing) (JJ cytostatic)) (NP (QP (RB rather) (CD one)) (NN tumor) (NN regression))))))))) |ET| |BS|8:C04 50:M01.643 96:I03.784 104:C04.557.470.200.025.255 279:D27.888.569.100 288:C23.550.288 469:D08.811.913.696 845:D27.888.569.199 846:F01.393.784|ES| 2:1 7:1 10:1 14:1 19:1 120:1 124:1 274:1 303:1 304:1 380:1 441:1 470:1 494:1 691:1 953:1 997:1 1010:1 1170:1 1592:1 2063:1 2998:1 2999:1 3000:1 3001:1 3002:1

-1 	|BT| (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ allows) (SBAR (S (NP (NN u)) (VP (VBP conclude) (SBAR (S (NP (JJ diosmin) (JJ dietary) (NN supplement)) (, ,) (VP (MD could) (VP (VBN used) (S (NP (JJ chemopreventive) (NN agent)) (VP (VBP prevent) (NP (NN hepatocarcinogenesis))))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 557:D02.241.081.069.600.150 715:D03.383.663.283.266.450.260.222 847:G07.203.300.456|ES| 2:1 19:1 131:1 476:1 691:1 728:1 733:1 900:1 908:1 1307:1 1946:1 1968:1 2243:1 2594:1 2695:1 3003:1 3004:1

-1 	|BT| (NP (NP (NP (DT The) (JJ present) (NN study) (NN offer) (NN strategy) (JJ novel) (NN CUR) (NN analogue)) (, ,) (PRN (-LRB- -LRB-) (NP (NN 1E) (CD ,4) (NN E)) (-RRB- -RRB-)) (NP (NP (NP (NN -1,5-bis) (-LRB- -LRB-) (NN 2-bromophenyl) (-RRB- -RRB-) (NN penta-1,4-dien-3-one)) (PRN (-LRB- -LRB-) (NP (NN GL63)) (-RRB- -RRB-))) (, ,) (NP (VBN used) (JJ potential) (NP (NP (JJ therapeutic) (NN agent) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))) (ADVP (FW vitro) (FW vivo))))) |ET| |BS|12:Z01.542.049 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500|ES| 2:1 10:1 14:1 19:1 131:1 216:1 303:1 304:1 378:1 441:1 476:1 541:1 691:1 728:1 827:1 891:1 1042:1 1114:1 1307:1 1380:1 3005:1 3006:1 3007:1 3008:1 3009:1 3010:1

-1 	|BT| (S (NP (DT The) (NN purpose) (NN investigation)) (VP (VBP investigate) (FRAG (NP (NP (JJ chemopreventive) (NN action) (JJ possible) (NN mechanism) (NN saffron) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN liver) (NN cancer) (NN rat))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 701:B01.650.940.800.575.100.549.500|ES| 10:1 14:1 18:1 19:1 162:1 409:1 459:1 691:1 836:1 849:1 1359:1 1497:1 1875:1 1946:1 1952:1 2013:1 2523:1 3011:1

-1 	|BT| (S (NP (DT The) (NN purpose) (NN study)) (VP (VBP evaluate) (NP (NP (NP (JJ anticancer) (NN potency) (NN mechanism) (JJ novel) (NN difluorodiarylidenyl) (NN piperidone)) (PRN (-LRB- -LRB-) (NP (NN H-4073)) (-RRB- -RRB-))) (S (NP (NP (NN N-hydroxypyrroline) (NN modification)) (PRN (-LRB- -LRB-) (NP (NN HO-3867)) (-RRB- -RRB-))) (NP (JJ human) (JJ ovarian) (NN cancer)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 179:D01.248.497.300.459.700 225:E05.337 259:D12.776.395.240.150.500 848:D03.383.621.808|ES| 10:1 14:1 18:1 19:1 36:1 131:1 162:1 691:1 890:1 891:1 1763:1 1880:1 2374:1 2796:1 3011:1 3012:1 3013:1 3014:1 3015:1 3016:1

-1 	|BT| (NP (NP (NP (DT The) (NN rate) (NN proliferation) (NN HT29) (JJ human) (NN colon) (NN cancer) (NN cell)) (SBAR (S (NP (VBN reduced) (JJ treated) (NN gamma-secretase) (NN inhibitor) (NN dibenzazepine)) (VP (VBP inhibit) (NP (NP (NN Notch) (NN signaling) (JJ small) (VBG interfering) (NN RNA)) (VP (VBD directed) (NP (NN Notch))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 117:D13.150.650.700 122:C14.280.383 125:D08.811.277.656.300.032 212:E01.370.225.500.385.500 792:A11.251.210.190.475|ES| 18:1 19:1 36:1 41:1 94:1 113:1 195:1 256:1 299:1 380:1 452:1 515:1 691:1 750:1 1099:1 1370:1 1866:1 3017:1 3018:1 3019:1 3020:1

-1 	|BT| (S (NP (DT The) (NN result)) (VP (VBD indicated) (SBAR (S (NP (NN 6-MSITC)) (VP (VBD exerted) (NP (NP (NP (JJ chemopreventive) (NN effect)) (JJ present) (JJ short-term) (NN colon) (NN carcinogenesis) (NN bioassay)) (, ,) (NP (NP (NN alteration) (NN cell) (NN proliferation) (NN activity) (NN drug)) (VP (VBG metabolizing) (NP (NN enzyme) (NN level)))))))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 67:D26 106:E05.091 212:E01.370.225.500.385.500 624:D27.505.696.706.018 649:E01.370.225.124.200 849:G08.686.785.760.769.490.500|ES| 2:1 19:1 75:1 94:1 101:1 113:1 191:1 207:1 249:1 299:1 399:1 691:1 951:1 1307:1 1541:1 1946:1 2102:1 2388:1 2931:1 3021:1 3022:1 3023:1

-1 	|BT| (S (NP (DT The) (JJ selective) (NN EGFR) (NN inhibitor) (NN Gefitinib)) (VP (VBD found) (S (VP (VBP prevent) (NP (NN hepatocarcinogenesis) (NN rat) (JJ cirrhotic) (NN liver)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700|ES| 19:1 37:1 187:1 380:1 691:1 733:1 836:1 849:1 900:1 1749:1 2968:1 3024:1

-1 	|BT| (S (NP (DT The) (NN study)) (VP (VBD suggested) (SBAR (S (NP (NN HO-3867)) (VP (MD may) (NP (NP (JJ useful) (JJ safe) (JJ effective) (JJ anticancer) (NN agent)) (JJ ovarian) (NN cancer) (NN therapy))))))) |ET| |BS|52:E02|ES| 18:1 19:1 130:1 131:1 491:1 691:1 728:1 925:1 1036:1 1639:1 1763:1 1880:1 2737:1 3016:1

-1 	|BT| (S (NP (DT The) (JJ sulfated) (NN polysaccharide) (NNP U.) (NN lactuca)) (VP (MD may) (SBAR (S (NP (JJ unique) (NN property) (VBG providing) (NN protection) (JJ DENA-induced) (JJ oxidative) (NN stress)) (VP (MD could) (VP (VB contribute) (NP (NN chemoprevention) (JJ experimental) (NN hepatocarcinogenesis)))))))) |ET| |BS|253:E02.319.162 554:D02.654.442.200 716:G03.495.710 803:D01.248.497.158.845 804:D09.698|ES| 19:1 263:1 450:1 491:1 691:1 841:1 870:1 900:1 908:1 1469:1 2522:1 2583:1 2734:1 2839:1 2840:1 2841:1 2842:1 3025:1 3026:1

-1 	|BT| (S (NP (DT The) (NN theme) (NN study)) (VP (VBP evaluate) (SBAR (S (NP (JJ therapeutic) (NN efficacy)) (VP (VBD nanoencapsulated) (FRAG (NP (JJ flavonoidal) (NN quercetin)) (-LRB- -LRB-) (NP (NP (NP (CD 3,5,7,3) ('' ') (NN ,4)) ('' ') (PRN (: -) (NP (NP (NN pentahydroxy) (NN flavone)) (, ,) (NP (NN QC))) (-RRB- -RRB-))) (S (VP (VBG combating) (NP (JJ DEN-induced) (NN hepatocarcinogenesis) (NN rat))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 225:E05.337 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 533:D03.383.663.283.266.450.284.777 850:D03.383.663.283.266.450.260 851:J01.897.608|ES| 2:1 10:1 14:1 19:1 131:1 541:1 691:1 849:1 890:1 900:1 1884:1 2304:1 2735:1 3027:1 3028:1 3029:1 3030:1 3031:1 3032:1 3033:1

-1 	|BT| (NP (NP (JJ Therapeutic) (NN effect) (JJ multi-targeted) (NN imidazolium) (NN compound) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255|ES| 19:1 75:1 303:1 304:1 2433:1 2993:1 3034:1 3035:1

-1 	|BT| (S (NP (NP (NN Therapy)) (VP (VBG targeting) (NP (NN Vav3) (NN combination) (NN docetaxel)))) (VP (MD may) (NP (JJ practical) (NN implication) (NN managing) (JJ castration-resistant) (NN prostate) (NN cancer)))) |ET| |BS|618:E02.186 852:C04.588.945.440.770.500|ES| 18:1 19:1 77:1 85:1 491:1 530:1 616:1 3036:1 3037:1 3038:1 3039:1 3040:1 3041:1

-1 	|BT| (S (NP (DT These) (NNS data)) (VP (VBP suggest) (NP (NP (JJ genetic) (NN amplification) (NN TYMS) (JJ major) (NN mechanism) (NN 5-FU) (NN resistance)) (PP (FW vivo) (NP (NP (JJ important) (NN implication) (NN management) (JJ colorectal) (NN cancer) (NN patient)) (JJ recurrent) (NN disease)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 288:C23.550.288 392:G05.355.315.250 496:C23.550.291.937 560:D03.383.742.698.875.404 713:D08.811.913.555.500.862 853:N04.590.607|ES| 17:1 18:1 19:1 85:1 120:1 162:1 378:1 462:1 792:1 793:1 796:1 864:1 902:1 921:1 998:1 1094:1 1753:1 2308:1 3042:1 3043:1

-1 	|BT| (NP (DT These) (VBG finding) (S (VP (VBP confirm) (NP (NN hypothesis) (NN ODC) (NN polymorphism) (JJ genetic) (NN marker) (NN colon) (NN cancer) (NN risk))) (, ,) (NP (NP (NP (NN support) (NN use) (NN ODC) (NN inhibitor) (NN aspirin)) (, ,) (NP (NP (JJ nonsteroidal) (JJ antiinflammatory) (NN drug)) (PRN (-LRB- -LRB-) (NP (NNS NSAIDs)) (-RRB- -RRB-))) (, ,)) (NN combination) (NN strategy) (NN colon) (NN cancer) (NN prevention)))) |ET| |BS|61:E05.318.740.600.800 149:G05.360.340.024.340.364.875.890 158:D23.101 307:G05.365.795 670:D02.455.426.559.389.657.410.595.176 796:D27.505.696.663.850.014.040.500|ES| 2:1 10:1 14:1 18:1 19:1 113:1 171:1 191:1 380:1 530:1 534:1 792:1 864:1 927:1 1060:1 1114:1 1364:1 1474:1 1659:1 2477:1 2487:1 2697:1 2966:1 3044:1 3045:1 3046:1

-1 	|BT| (PP (DT These) (S (VP (VBG finding) (S (VP (VBP suggest) (SBAR (S (NP (NN sulindac)) (VP (MD may) (NP (NP (JJ effective) (NN agent) (NN colon) (NN cancer) (NN prevention)) (NP (JJ human) (JJ low) (NN 15-PGDH)))))))) (, ,) (S (NP (NN use)) (MD may) (ADVP (RB also)) (VP (VBN associated) (NP (JJ inflammatory) (NN lesion) (NN colon))))))) |ET| |BS|46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 251:D02.455.426.559.847.486.875|ES| 2:1 5:1 18:1 19:1 36:1 113:1 133:1 169:1 491:1 531:1 728:1 792:1 796:1 869:1 927:1 1131:1 1474:1 1639:1 1659:1 2430:1

-1 	|BT| (NP (NP (DT These) (NN observation) (NN show)) (, ,) (NP (JJ first) (NN time)) (, ,) (S (NP (NP (NN CP-31398) (NN posse) (JJ significant) (JJ dose-dependent) (JJ chemopreventive) (NN activity)) (JJ well-established) (NN colon) (NN cancer) (NN model) (NN combination) (JJ low-dose) (NN CP-31398) (NN celecoxib)) (ADVP (RB significantly)) (VP (VBD enhanced) (NP (NN colon) (NN cancer) (JJ chemopreventive) (NN efficacy))))) |ET| |BS|322:G01.910 429:N04.761.559.590.900 430:E05.581.249 684:D02.065.884.247|ES| 2:1 18:1 19:1 72:1 113:1 124:1 135:1 385:1 399:1 429:1 530:1 792:1 816:1 1081:1 1477:1 1770:1 1946:1 2304:1 2807:1 2824:1 3047:1 3048:1 3049:1

-1 	|BT| (S (NP (DT These)) (VP (VBP result) (ADVP (RB also)) (VP (VBP support) (NP (NN role) (NNP BMX) (JJ potential) (NN drug) (NN candidate) (NN use) (NN combination) (NN cisplatin) (NN treatment) (JJ human) (NN lung) (NN cancer))))) |ET| |BS|15:F01.829.316.616 52:E02 55:B01.050.150.900.649.801.400.112.400.400 67:D26 375:Z01.639.100 498:D01.210.375|ES| 5:1 18:1 19:1 31:1 36:1 101:1 191:1 328:1 530:1 546:1 792:1 827:1 1243:1 1364:1 1659:1 1761:1 3050:1

-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VP (VBP indicate) (SBAR (S (NP (NP (NN chitin)) (, ,) (NP (NN chitosan) (JJ related) (NN compound))) (VP (VBP exert) (NP (NP (JJ unequivocal) (JJ chemopreventive) (NN effect)) (NP (JJ heterocyclic) (JJ amine-induced) (NN hepatocarcinogenesis))))))) (, ,) (SBAR (S (NP (NN effect) (NN organ)) (VP (MD may) (SBAR (S (NP (NN tissue) (JJ specific) (JJ possible) (JJ inhibitory) (NN action) (JJ mammary) (NN gland)) (VP (VBD offset) (NP (NN promotion) (NN colon) (NN lesion) (NN development))))))))))) |ET| |BS|46:A03.556.124.526.356 98:A10 609:A01.236.249 624:D27.505.696.706.018 854:D05.750.078.139.500 855:D05.750.078.139 856:D02.092|ES| 2:1 19:1 35:1 75:1 101:1 113:1 272:1 419:1 491:1 540:1 592:1 792:1 900:1 1131:1 1359:1 1382:1 1479:1 1946:1 2013:1 2248:1 2337:1 2429:1 2433:1 2843:1 3051:1 3052:1 3053:1 3054:1 3055:1 3056:1

-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP indicate) (SBAR (S (NNP Valerian) (VP (VBP exhibit) (S (NP (JJ inhibitory) (NN effect) (NN rat) (NN hepatocarcinogenesis)) (VP (VBG inhibiting) (NP (JJ oxidative) (NN DNA) (NN damage)))) (, ,) (S (VP (VBG suppressing) (NP (NP (NN cell) (NN proliferation)) (VP (VBG inducing) (NP (NP (NP (NN apoptosis) (NN GST-P)) (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-))) (NN focus) (VBG activating) (NN GABA) (-LRB- -LRB-) (NN A) (-RRB- -RRB-) (JJ R-mediated) (NN signaling)))))))))))) |ET| |BS|39:G04.299.139.160 69:G02.111.087.800 122:C14.280.383 175:J01.897.280.500.269 183:G04.299.233.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 526:G05.355.180 599:M01.526.799.500 857:B01.650.940.800.575.100.955.888 858:B01.650.940.800.575.100.955.888 859:D02.241.081.114.500.350|ES| 2:1 10:1 14:1 19:1 69:1 75:1 89:1 94:1 101:1 195:1 299:1 587:1 666:1 792:1 849:1 880:1 900:1 1431:1 1479:1 1848:1 1864:1 1958:1 2250:1 2429:1 2583:1 3057:1 3058:1 3059:1 3060:1 3061:1

-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP provide) (SBAR (S (NP (JJ preclinical) (NN evidence)) (VP (VBP continue) (NP (NP (NN development) (NN alantolactone) (NN STAT3) (NN inhibitor)) (JJ potential) (JJ therapeutic) (NN agent) (NN breast) (NN cancer)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 82:D12.644.360.024.342.300|ES| 18:1 19:1 23:1 35:1 38:1 101:1 251:1 380:1 541:1 711:1 728:1 792:1 827:1 1494:1 2686:1 3062:1

-1 	|BT| (S (NP (DT These)) (VP (VBP result) (NP (NP (NN show) (NN Cx32) (NN luteolin) (JJ suppressive) (NN role)) (NN inflammation) (, ,) (NN fibrosis) (NN hepatocarcinogenesis) (NN NASH) (NN progression)) (, ,) (S (VP (VBG suggesting) (NP (JJ potential) (JJ therapeutic) (NN application) (NNP NASH)))))) |ET| |BS|15:F01.829.316.616 16:C23.550.291.656 52:E02 525:C23.550.470 691:C23.550.355 704:D03.383.663.283.266.450.260.555|ES| 2:1 19:1 31:1 48:1 101:1 165:1 429:1 541:1 792:1 827:1 900:1 949:1 1009:1 1974:1 2547:1 3063:1 3064:1 3065:1

-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN simvastatin)) (VP (MD could) (NP (NP (JJ potential) (JJ chemopreventive) (JJ therapeutic) (NN agent)) (NP (NP (NNP CAC)) (NP (ADVP (RB well)) (NP (ADJP (FW de) (FW novo)) (NN colon) (NN cancer))))))))))) |ET| |BS|52:E02 754:D02.455.426.559.847.638.400.900 860:Z01.107.567.875.500.200 861:Z01.542.315|ES| 18:1 19:1 101:1 113:1 541:1 728:1 787:1 792:1 796:1 827:1 908:1 1946:1 2679:1 3066:1 3067:1 3068:1

-1 	|BT| (S (NP (NNS Thiazolidinediones)) (VP (VBP inhibit) (NP (NN hepatocarcinogenesis) (NN hepatitis) (NN B) (JJ virus-transgenic) (NN mouse) (NN peroxisome) (JJ proliferator-activated) (NN receptor) (JJ gamma-independent) (NN regulation) (NN nucleophosmin)))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 99:B01.050.050.136.500 122:C14.280.383 142:I01.880.604 719:D12.776.826.239.588 862:D02.886.675.933 863:B04.280.375.650.425|ES| 19:1 52:1 186:1 438:1 763:1 900:1 1370:1 1801:1 1887:1 2048:1 3069:1 3070:1 3071:1 3072:1

-1 	|BT| (S (NP (NN Thioredoxin) (NN reductase) (CD 1)) (VP (VBZ protects) (VP (ADVP (RB chemically)) (VBN induced) (NN hepatocarcinogenesis) (PP (IN via) (NP (NN control) (JJ cellular) (NN redox) (NN homeostasis)))))) |ET| |BS|41:A11 152:G07.700.345 864:D08.811.682.667.750.500 865:G02.149.767.650|ES| 19:1 96:1 98:1 289:1 412:1 500:1 596:1 900:1 1863:1 2581:1 3073:1 3074:1 3075:1

-1 	|BT| (S (ADVP (RB Thus)) (, ,) (VP (VBP result) (NP (NN support) (JJ future) (NN utilization) (NN decorin) (NN antitumor) (NN agent) (NN liver) (NN cancer)))) |ET| |BS|354:I01.320 375:Z01.639.100 660:D27.505.954.248 708:D12.776.395.650.750.625|ES| 2:1 18:1 19:1 101:1 728:1 836:1 1190:1 1364:1 1691:1 2244:1 2901:1 3076:1

-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN PKCbetaII) (JJ important) (NN target) (NN colon) (NN cancer) (NN chemoprevention) (JJ PKCbeta-selective) (NN inhibitor) (NN enzastaurin)) (VP (MD may) (VP (VB represent) (NP (NP (JJ effective) (JJ chemopreventive) (NN agent) (NN patient)) (JJ high) (NN risk) (NN colon) (NN cancer))))) |ET| |BS|12:Z01.542.049 61:E05.318.740.600.800 253:E02.319.162 866:D08.811.913.696.620.682.700.725.049 867:D08.811.913.696.620.682.700.725.049 868:M01.380.600|ES| 2:1 18:1 19:1 113:1 120:1 160:1 171:1 178:1 380:1 491:1 728:1 799:1 870:1 902:1 1639:1 1691:1 1946:1 2855:1 3077:1 3078:1

-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NP (NN combination) (NN As2O3) (NN Ad-PML) (JJ synergistic) (JJ inhibitory) (NN effect)) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))) (, ,) (S (VP (ADVP (RB possibly)) (VBG resulting) (NP (NN regulation) (JJ apoptotic) (NN gene) (NN expression)))) (VP (VBD enhanced) (NP (NNP HCC) (NN apoptosis)))) |ET| |BS|39:G04.299.139.160 104:C04.557.470.200.025.255 140:G05.355.315|ES| 2:1 9:1 10:1 14:1 19:1 75:1 89:1 115:1 303:1 304:1 384:1 385:1 438:1 441:1 530:1 1548:1 1691:1 2012:1 2223:1 2429:1 3079:1 3080:1

-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN study)) (VP (VBP show) (NP (JJ myrtenal) (NN ability) (VBP suppress) (JJ hepatocellular) (NN carcinoma) (NN rat)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 385:F02.784.629.131|ES| 2:1 19:1 131:1 303:1 304:1 429:1 849:1 1300:1 1691:1 2441:1 2682:1

-1 	|BT| (NP (NP (NNP Thymidylate) (NN synthase)) (, ,) (NP (NN thymidine) (NN phosphorylase)) (, ,) (NP (NN dihydropyrimidine) (NN dehydrogenase) (NN expression)) (, ,) (NP (JJ histological) (NN tumour) (NN regression) (JJ 5-FU-based) (JJ neo-adjuvant) (JJ chemoradiotherapy) (JJ rectal) (NN cancer))) |ET| |BS|8:C04 333:D01.045 560:D03.383.742.698.875.404 561:E02.186.079.500 713:D08.811.913.555.500.862 846:F01.393.784 869:D08.811.913.400.725.850.500 870:D08.811.682.660.350|ES| 2:1 18:1 19:1 66:1 115:1 1011:1 1986:1 1987:1 1988:1 1989:1 3002:1 3081:1 3082:1 3083:1 3084:1 3085:1 3086:1

-1 	|BT| (S (NP (NNP Thymoquinone)) (VP (VBZ reduces) (SBAR (S (NP (NN mouse) (NN colon) (NN tumor) (NN cell) (NN invasion)) (VP (VBZ inhibits) (NP (NN tumor) (NN growth) (JJ murine) (NN colon) (NN cancer) (NN model))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 41:A11 45:G07.700.320.249 51:C04.588.274.476.411.307.180 122:C14.280.383|ES| 7:1 18:1 19:1 52:1 72:1 94:1 102:1 113:1 142:1 615:1 620:1 627:1 3087:1

-1 	|BT| (NP (NP (S (VP (TO To) (ADVP (RBR better)) (VP (VB understand) (NP (NP (JJ anticancer) (NN activity) (NNP Levamisole)) (PRN (-LRB- -LRB-) (NP (NNP LMS)) (-RRB- -RRB-)))))) (, ,) (NP (NP (NN serf) (JJ adjuvant) (NN colon) (NN cancer) (NN therapy) (NN combination) (NN 5-Fluorouracil)) (, ,) (NP (NP (NN study) (NN analysis) (NNP LMS) (POS ')) (NN ability)) (S (VP (VBP induce) (NP (NP (NN apoptosis) (NN growth) (NN arrest)) (NP (VBN cultured) (JJ human) (JJ micro) (: -) (NP (JJ macrovascular) (JJ endothelial) (NN cell) (PRN (-LRB- -LRB-) (NP (NNS ECs)) (-RRB- -RRB-)) (NN fibroblast))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 239:F02.463.188.357 385:F02.784.629.131 560:D03.383.742.698.875.404 618:E02.186 685:D27.505.696.477.067 687:D26.650.064 871:D02.886.675.346 872:A11.329.228 873:A11.436.275|ES| 2:1 10:1 14:1 18:1 19:1 36:1 89:1 94:1 102:1 113:1 130:1 131:1 243:1 399:1 530:1 602:1 661:1 828:1 829:1 882:1 904:1 1232:1 1300:1 1489:1 1880:1 2213:1 2404:1 2479:1 3088:1 3089:1 3090:1 3091:1 3092:1 3093:1

-1 	|BT| (S (S (VP (TO To) (VP (VB improve) (NP (JJ clinical) (NN outcome))))) (, ,) (NP (NN investigation) (JJ potential) (NN bortezomib) (NN therapy) (NN thyroid) (NN cancer)) (ADVP (RB clearly)) (VP (VBD warranted))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 225:E05.337 675:D01.029.260.110.500|ES| 2:1 18:1 19:1 84:1 130:1 547:1 827:1 828:1 969:1 1497:1 2466:1 2816:1 2838:1 3094:1

-1 	|BT| (S (VP (ADVP (RB Together)) (, ,) (VBG finding) (VP (VBP suggest) (SBAR (S (NP (NN silibinin)) (VP (VBZ inhibits) (NP (NP (NN growth) (NN SW480) (NN tumor)) (VP (VBG carrying) (NP (JJ mutant) (NN APC) (NN gene) (NN down-regulating) (NN CDK8) (NN beta-catenin) (NN signaling)))) (, ,) (ADVP (RB therefore)) (, ,) (VP (MD could) (NP (JJ effective) (NN agent) (NN CRC))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 12:Z01.542.049 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 45:G07.700.320.249 69:G02.111.087.800 122:C14.280.383 247:G01.374.676.530 351:A17.360|ES| 2:1 7:1 9:1 11:1 19:1 60:1 102:1 195:1 218:1 245:1 615:1 728:1 796:1 811:1 850:1 908:1 927:1 1639:1 2635:1 3095:1 3096:1 3097:1 3098:1

-1 	|BT| (S (NP (NN Tongue) (NN cancer) (NN prevention) (NN study)) (VP (VBD conducted) (NP (NP (JJ zinc-deficient) (NN rat)) (NP (ADJP (RB previously) (VBN exposed)) (NN tongue) (NN carcinogen) (NN celecoxib) (NN treatment))) (VP (PP (IN without) (NP (NN zinc) (NN replenishment))) (, ,) (NP (NP (NN zinc) (NN replenishment)) (ADVP (RB alone)))))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 52:E02 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 684:D02.065.884.247 874:D01.268.556.940 875:A03.556.500.885 876:F01.145|ES| 2:1 18:1 19:1 131:1 241:1 546:1 849:1 1195:1 1474:1 1527:1 2125:1 2807:1 3099:1 3100:1 3101:1 3102:1 3103:1 3104:1 3105:1

-1 	|BT| (S (NP (NP (NP (NN Treatment) (NN mouse) (NN EGFR-inhibitor)) (PRN (-LRB- -LRB-) (NP (NN EGFRi)) (-RRB- -RRB-))) (, ,) (NP (NN Canertinib)) (, ,)) (VP (VBP 1h) (ADJP (JJ post-APAP)) (VP (VBD resulted) (NP (NP (JJ robust) (NN inhibition) (NN EGFR-activation) (JJ striking) (NN reduction)) (JJ APAP-induced) (NN liver) (NN injury))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 43:F01.145.544 52:E02 242:A03.620 661:D02.065.199.092.040 877:N03.540.571.608|ES| 2:1 10:1 14:1 19:1 52:1 103:1 370:1 594:1 836:1 2416:1 3106:1 3107:1 3108:1 3109:1 3110:1 3111:1 3112:1 3113:1 3114:1 3115:1

-1 	|BT| (S (NP (NN Troglitazone)) (VP (VBZ inhibits) (NP (NN tumor) (NN growth) (JJ hepatocellular) (NN carcinoma)) (ADVP (FW vitro) (FW vivo)))) |ET| |BS|8:C04 45:G07.700.320.249 104:C04.557.470.200.025.255 122:C14.280.383|ES| 7:1 19:1 102:1 216:1 303:1 304:1 378:1 615:1 3116:1

-1 	|BT| (NP (NP (NP (NNP UNLABELLED)) (: :) (NP (NP (NP (JJ Antidiabetic) (NNS thiazolidinediones)) (PRN (-LRB- -LRB-) (NP (NN TZD)) (-RRB- -RRB-))) (PP (FW vitro) (NP (NP (JJ antiproliferative) (NN effect) (JJ epithelial) (NN cancer)) (, ,) (PP (VBG including) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))))) |ET| |BS|104:C04.557.470.200.025.255 862:D02.886.675.933 878:D27.505.696.422|ES| 2:1 10:1 14:1 18:1 19:1 75:1 104:1 127:1 216:1 303:1 304:1 441:1 561:1 2266:1 3117:1 3118:1 3119:1 3120:1

-1 	|BT| (NP (NP (NP (NP (JJ Ursodeoxycholic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN UDCA)) (-RRB- -RRB-))) (NP (NP (JJ known) (NN suppressor) (JJ cholestatic) (NN liver) (NN disease)) (JJ colorectal) (NN cancer) (NN development)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 650:C06.552 737:D04.808.105.225.272.962 879:C06.130.120.135|ES| 10:1 14:1 17:1 18:1 19:1 35:1 556:1 700:1 836:1 998:1 1275:1 2631:1 3121:1 3122:1

-1 	|BT| (S (NP (NN Valerian)) (VP (VBZ inhibits) (NP (NP (NP (NN rat) (NN hepatocarcinogenesis) (VBG activating) (NN GABA)) (PRN (-LRB- -LRB-) (NP (NN A)) (-RRB- -RRB-))) (NP (JJ receptor-mediated) (NN signaling))))) |ET| |BS|69:G02.111.087.800 122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 857:B01.650.940.800.575.100.955.888 858:B01.650.940.800.575.100.955.888 880:D12.776.157.530.400.175.562|ES| 10:1 14:1 19:1 69:1 195:1 615:1 849:1 900:1 1958:1 3057:1 3060:1 3123:1

-1 	|BT| (NP (NP (NN Vanadium) (JJ chemopreventive) (JJ early) (NN stage) (JJ 2-AAF-induced) (NN hepatocarcinogenesis) (NN rat))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 837:D01.268.556.920 881:D02.065.064.150|ES| 19:1 849:1 900:1 1128:1 1129:1 1946:1 3124:1 3125:1

-1 	|BT| (S (NP (PRP We)) (VP (VBD demonstrated) (NP (JJ possible) (NP (NP (JJ beneficial) (NN use) (NN pamidronate) (NN treatment) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) |ET| |BS|52:E02 104:C04.557.470.200.025.255|ES| 10:1 14:1 19:1 303:1 304:1 441:1 546:1 843:1 984:1 1175:1 1359:1 1659:1 3126:1

-1 	|BT| (S (NP (PRP We)) (VP (VBP find) (SBAR (S (JJ enzastaurin) (ADVP (RB potently)) (VP (VBZ reduces) (NP (NP (JJ azoxymethane-induced) (NN colon) (NN tumor) (NN initiation) (NN progression)) (VP (VBG inhibiting) (NP (JJ PKCbetaII-mediated) (NN tumor) (NN cell) (NN proliferation) (NN beta-catenin) (NN accumulation))))))))) |ET| |BS|8:C04 16:C23.550.291.656 23:D12.776.091.249 51:C04.588.274.476.411.307.180 122:C14.280.383 132:D02.172.080 183:G04.299.233.750 866:D08.811.913.696.620.682.700.725.049|ES| 7:1 19:1 48:1 60:1 94:1 113:1 142:1 299:1 637:1 843:1 880:1 2120:1 2533:1 2855:1 3127:1 3128:1 3129:1

-1 	|BT| (S (S (S (NP (PRP We)) (VP (VBD found) (S (VP (VBG impairing) (NP (JJ autophagy) (NNS hepatocytes)))))) (VP (MD would) (VP (VB induce) (NP (JJ oxidative) (NN stress) (NN DNA) (NN damage))))) (, ,) (NP (VBD followed) (NN initiation) (NN hepatocarcinogenesis)) (, ,) (VP (MD could) (VP (VBD suppressed) (NP (NN antioxidant) (NN N-acetylcysteine))))) |ET| |BS|262:A11.436.348 390:G04.299.139.399 526:G05.355.180 700:D27.505.519.217 716:G03.495.710 791:D02.886.030.230.259|ES| 2:1 19:1 37:1 243:1 307:1 637:1 666:1 775:1 843:1 866:1 894:1 900:1 908:1 1317:1 1848:1 2521:1 2522:1 2583:1 3130:1 3131:1

-1 	|BT| (S (NP (PRP We)) (ADVP (RB recently)) (VP (VBD demonstrated) (NP (NP (NP (JJ total) (NNP Astragalus) (NN saponin)) (PRN (-LRB- -LRB-) (NP (NNP AST)) (-RRB- -RRB-))) (NN posse) (JJ anticarcinogenic) (JJ proapoptotic) (NN property) (JJ human) (NN colon) (NN cancer) (NN cell) (NN tumor) (NN xenograft)))) |ET| |BS|8:C04 41:A11 55:B01.050.150.900.649.801.400.112.400.400 92:E04.936.764 93:A01.941.875 688:B01.650.940.800.575.100.401.087 689:A02.835.232.043.300.710.780 882:D09.408.782|ES| 7:1 10:1 14:1 18:1 19:1 36:1 94:1 113:1 265:1 333:1 772:1 841:1 843:1 1175:1 1885:1 2493:1 3048:1 3132:1 3133:1 3134:1

-1 	|BT| (S (NP (PRP We)) (ADVP (RB also)) (VP (VBN shown) (SBAR (S (NP (NP (JJ ursodeoxycholic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN UDCA)) (-RRB- -RRB-))) (VP (VBD prevented) (SBAR (S (NP (JJ AOM-induced) (NN colon) (NN cancer)) (VP (VBD suppressed) (NP (NN Cox-2) (NN induction)))))))))) |ET| |BS|132:D02.172.080 737:D04.808.105.225.272.962|ES| 5:1 10:1 14:1 18:1 19:1 62:1 113:1 237:1 307:1 736:1 843:1 1275:1 1944:1 2630:1 2631:1 3135:1

-1 	|BT| (S (NP (PRP We)) (VP (VBD shown) (SBAR (S (NP (NP (JJ dietary) (NN fish) (NN oil) (NN pectin)) (PRN (-LRB- -LRB-) (NP (NN FP)) (-RRB- -RRB-))) (VP (VBZ protects) (NP (NP (JJ radiation-enhanced) (NN colon) (NN cancer)) (VP (VBG upregulating) (NP (NN apoptosis) (JJ colonic) (NN mucosa))))))))) |ET| |BS|38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 46:A03.556.124.526.356 281:E02.815 302:A10.615.550 489:B01.050.150.900.493 595:G07.203.650.240 883:D10.212.302.380 884:Z01.639.760.815 885:G01.358.500.505 886:D10.627.430 887:G01.750|ES| 10:1 14:1 18:1 19:1 89:1 113:1 237:1 579:1 677:1 843:1 1863:1 2594:1 2614:1 3136:1 3137:1 3138:1 3139:1 3140:1

-1 	|BT| (S (NP (PRP We)) (VP (VBP hypothesize) (SBAR (S (NP (NP (NN NF-kappaB) (NN suppression) (JJ novel) (NN inhibitor) (NN dimethylaminoparthenolide)) (PRN (-LRB- -LRB-) (NP (NN DMAPT)) (-RRB- -RRB-))) (VP (MD may) (VP (VB enhance) (NP (NN effect) (NN gemcitabine) (JJ pancreatic) (NN cancer)))))))) |ET| |BS|210:D12.776.260.600 259:D12.776.395.240.150.500|ES| 10:1 14:1 18:1 19:1 75:1 380:1 467:1 491:1 714:1 843:1 891:1 1690:1 2453:1 2504:1 2505:1 3141:1 3142:1

-1 	|BT| (S (NP (PRP We)) (VP (VBD observed) (NP (NP (NP (JJ significant) (NN reduction) (NN number) (NN size) (JJ small) (JJ intestinal) (NN polyp) (NN APC)) (PRN (-LRB- -LRB-) (NP (NP (NN min)) (CC +) (: /) (: -)) (-RRB- -RRB-))) (NN mouse) (VBN treated) (CC either) (NP (NP (NP (NP (NN celecoxib)) (PRN (-LRB- -LRB-) (NP (JJ selective) (NN COX-2) (NN inhibitor)) (-RRB- -RRB-))) (NN erlotinib)) (PRN (-LRB- -LRB-) (NP (NP (NN Tarceva)) (, ,) (NP (NN EGFR) (NN inhibitor))) (-RRB- -RRB-)))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 52:E02 193:C23.300.825.411 349:D27.505.519.389.310.500 684:D02.065.884.247 888:D03.438.786.375|ES| 2:1 10:1 11:1 14:1 19:1 39:1 52:1 76:1 109:1 135:1 187:1 261:1 370:1 380:1 646:1 647:1 750:1 843:1 1099:1 1749:1 2142:1 2342:1 2807:1 3143:1 3144:1

-1 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD showed) (SBAR (S (NP (NN embelin)) (VP (VBZ inhibits) (NP (NN growth) (NN colon) (NN cancer) (NN cell) (NN vitro))))) (, ,) (VP (ADVP (RB effectively)) (VBZ suppresses) (NP (JJ 1,2-dimethylhydrazine) (JJ dihydrochloride-induced) (NN colon) (NN carcinogenesis) (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 41:A11 45:G07.700.320.249 46:A03.556.124.526.356 122:C14.280.383|ES| 2:1 18:1 19:1 52:1 94:1 102:1 113:1 132:1 207:1 216:1 615:1 686:1 843:1 1527:1 2642:1 2889:1 2977:1 3145:1

-1 	|BT| (S (NP (PRP We)) (VP (VP (VBP propose) (SBAR (S (NP (JJ estrogen-mediated) (NN inhibition) (NN IL-6) (NN production) (NNS KCs)) (VP (VBZ reduces) (NP (NP (NN liver) (NN cancer) (NN risk) (NN female)) (, ,) (NP (NP (NN finding)) (VP (MD may) (VP (VBN used))))))))) (VP (VBP prevent) (NP (NN HCC) (NN male))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 61:E05.318.740.600.800 104:C04.557.470.200.025.255 201:D12.644.276.374.465.224 889:D27.505.696.399.472.277|ES| 2:1 18:1 19:1 103:1 142:1 171:1 441:1 476:1 491:1 733:1 836:1 843:1 927:1 1402:1 1404:1 2677:1 3146:1 3147:1 3148:1 3149:1

-1 	|BT| (S (NP (PRP We)) (VP (VBP report) (NP (NP (JJ autophagy) (VBN involved) (JJ NAC1-mediated) (NN resistance) (NN cisplatin)) (, ,) (NP (ADJP (RB commonly) (VBN used)) (JJ chemotherapeutic) (NN drug) (NN treatment) (JJ ovarian) (NN cancer))))) |ET| |BS|52:E02 67:D26 151:E02.319 390:G04.299.139.399 498:D01.210.375|ES| 2:1 15:1 18:1 19:1 191:1 417:1 476:1 546:1 774:1 843:1 1094:1 1317:1 1760:1 1761:1 1762:1 1763:1

-1 	|BT| (S (NP (PRP We)) (VP (VBD studied) (NP (NP (NN mechanism) (VBG underlying) (NN inhibition) (NN diethylnitrosamine) (-LRB- -LRB-) (NN DEN) (-RRB- -RRB-) (: -)) (VBN induced) (NN hepatocarcinogenesis) (NN lycopene) (NN rat)))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 43:F01.145.544 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200|ES| 10:1 14:1 19:1 103:1 162:1 401:1 409:1 435:1 843:1 849:1 900:1 1875:1 1952:1 2566:1

-1 	|BT| (S (NP (PRP We)) (VP (VBP suggest) (SBAR (S (NP (NN fisetin)) (VP (MD could) (NP (JJ useful) (NN agent) (NN prevention) (NN treatment) (NN colon) (NN cancer))))))) |ET| |BS|52:E02|ES| 18:1 19:1 113:1 546:1 728:1 796:1 843:1 908:1 1036:1 1474:1 2978:1

-1 	|BT| (S (NP (NP (NNP Zerumbone)) (, ,) (NP (JJ tropical) (NN ginger) (NN sesquiterpene)) (, ,)) (VP (VBZ inhibits) (NP (NN colon) (NN lung) (NN carcinogenesis) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 122:C14.280.383 182:A04.411 762:D02.455.849.765 890:B01.650.940.800.575.100.975.900.444|ES| 2:1 19:1 52:1 113:1 207:1 328:1 615:1 2687:1 3150:1 3151:1 3152:1

1 	|BT| (S (NP (NN Protein) (NN kinase) (NN D1)) (VP (VBZ attenuates) (NP (NP (NN tumorigenesis) (NN colon) (NN cancer)) (VP (VBG modulating) (NP (NN beta-catenin/T) (NN cell) (NN factor) (NN activity)))))) |ET| |BS|23:D12.776.091.249 32:C04.697.098.500 33:C04.697.098 68:A11.118.637.555.567.569 1063:D08.811.913.696.620.682|ES| 18:1 19:1 78:1 94:1 113:1 185:1 399:1 470:1 744:1 2423:1 2435:1 2911:1 3724:1

1 	|BT| (NP (NP (NN PURPOSE) (: :)) (NP (NP (NP (NP (JJ Fatty) (NN acid) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN FAS)) (-RRB- -RRB-))) (NP (JJ overexpressed) (NN lung) (NN cancer))) (, ,) (VP (VBD investigated) (NP (JJ potential) (NN use) (NN FAS) (NN inhibitor) (NN chemoprevention) (NN lung) (NN cancer))))) |ET| |BS|253:E02.319.162 921:D08.811.682.664.500.772 922:D10.251|ES| 2:1 10:1 14:1 18:1 19:1 25:1 66:1 104:1 328:1 380:1 403:1 687:1 827:1 870:1 1275:1 1659:1 3725:1 3726:1

1 	|BT| (NP (NP (NP (NP (NN PURPOSE) (: :)) (NN Obesity) (JJ related) (JJ metabolic) (NN abnormality)) (, ,) (PP (VBG including) (NP (NP (NN insulin) (NN resistance)) (VP (NN activation) (NP (NP (NP (JJ insulin-like) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN IGF)) (-RRB- -RRB-))) (: /) (NP (NP (NP (NN IGF-I) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN IGF-IR)) (-RRB- -RRB-))) (NN axis) (, ,) (NN risk) (NN factor) (NN colon) (NN cancer)))))))) |ET| |BS|254:C16.131 409:E05.318.740.600.800.725 518:D08.811.913.696.620.682.725.400.185 564:C18.654.726.500 579:A02.835.232.834.151.383 581:D12.644.276.937 678:C18.452.394.968.500 1064:Z01.252.245.500.350 1065:D01.268.556.401|ES| 2:1 10:1 14:1 18:1 19:1 102:1 104:1 113:1 171:1 185:1 186:1 225:1 419:1 561:1 687:1 1027:1 1094:1 2006:1 2089:1 2093:1 2364:1 3727:1 3728:1 3729:1 3730:1

1 	|BT| (S (NP (NP (NN PURPOSE) (: :)) (NP (NP (NP (NN Signal) (NN transducer) (NN activator) (NN transcription-3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (NP (JJ downstream) (NN growth) (NN factor) (NN cytokine) (NN receptor))) (, ,)) (VP (VBZ regulates) (NP (NP (JJ key) (JJ oncogenic) (NN pathway) (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))))) |ET| |BS|82:D12.644.360.024.342.300 110:C04.588.894.797.520.109.220.249 209:G02.111.087.847 250:E07.305.812 279:D27.888.569.100 897:Z01.252.245.500.375 1066:D12.776.543.750.705.852|ES| 2:1 10:1 14:1 18:1 19:1 94:1 102:1 104:1 159:1 185:1 186:1 251:1 328:1 329:1 383:1 560:1 603:1 687:1 694:1 860:1 861:1 953:1 2676:1 2960:1 3731:1

1 	|BT| (NP (NP (NP (JJ Quantitative) (NN analysis) (JJ basic) (NN fibroblast) (NN growth) (NN factor) (JJ vascular) (JJ endothelial) (NN growth) (NN factor)) (NP (JJ human) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 1067:D12.644.276.624.120|ES| 17:1 18:1 19:1 36:1 102:1 185:1 661:1 1251:1 2213:1 3092:1 3732:1 3733:1

1 	|BT| (NP (NP (NP (VBN Reduced) (NN expression) (NN cyclooxygenase) (CD 2) (NN protein) (JJ hereditary) (JJ nonpolyposis) (JJ colorectal) (NN cancer)) (JJ relative) (JJ sporadic) (NN cancer))) |ET| |BS|7:D12.776 24:D08.811.600.720.750 524:C04.588.274.476.411.307.190|ES| 4:1 17:1 18:1 19:1 115:1 148:1 725:1 1531:1 1845:1 1846:1 3180:1 3734:1

1 	|BT| (S (NP (NN Regrowth) (JJ 5-fluorouracil-treated) (JJ human) (NN colon) (NN cancer) (NN cell)) (VP (VBD prevented) (NP (NP (NN combination) (NN interferon) (NN gamma)) (, ,) (NP (NN indomethacin)) (, ,) (NP (NN phenylbutyrate))))) |ET| |BS|41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 560:D03.383.742.698.875.404 795:D03.438.473.420 1033:D12.644.276.374.440.893 1068:D02.241.223.651|ES| 2:1 18:1 19:1 36:1 94:1 113:1 530:1 1944:1 2305:1 2389:1 2792:1 3735:1 3736:1 3737:1

1 	|BT| (NP (NP (NNS RESULTS) (: :)) (NP (NP (NN 5-LOX) (VBN overexpressed) (JJ adenomatous) (NN polyp) (NN cancer)) (NP (VBN compared) (JJ normal) (JJ colonic) (NN mucosa)))) |ET| |BS|46:A03.556.124.526.356 302:A10.615.550 548:D08.811.682.664.500.848 551:C04.557.470.035.215|ES| 18:1 19:1 25:1 50:1 57:1 104:1 118:1 579:1 647:1 677:1 710:1 3390:1

1 	|BT| (S (NP (NNS RESULTS)) (: :) (S (NP (NN Microarray) (NN analysis)) (VP (VBD revealed) (SBAR (S (NP (NP (NN osteopontin)) (, ,) (NP (NN marker) (NN colon) (NN cancer) (NN progression)) (, ,)) (VP (VBD down-regulated) (NP (NP (NP (NN polyp) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN Delta14)) (: /) (CC +) (-RRB- -RRB-))) (NN mouse) (VBN given) (NN parecoxib)) (NP (VBN compared) (NN control)))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 142:I01.880.604 158:D23.101 350:D12.644.276.374.625 351:A17.360 444:C23.300.825 718:E05.588.570|ES| 2:1 10:1 14:1 18:1 19:1 29:1 48:1 50:1 52:1 104:1 113:1 275:1 280:1 281:1 289:1 534:1 647:1 661:1 710:1 1160:1 1283:1 3738:1 3739:1

1 	|BT| (NP (NP (NNS RESULTS) (: :)) (S (NP (NN Nestin) (NN expression)) (ADVP (RB significantly)) (VP (VBD associated) (NP (NP (JJ poor) (NN survival) (NN patient) (JJ triple-negative) (NN breast) (NN cancer)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.01)))) (-RRB- -RRB-)))))) |ET| |BS|50:M01.643 96:I03.784 159:I01.880.735.634 160:C04.588.180.788 1047:D05.750.078.593.540|ES| 10:1 14:1 18:1 19:1 23:1 26:1 104:1 115:1 120:1 124:1 169:1 274:1 311:1 315:1 545:1 581:1 710:1 3650:1

1 	|BT| (S (NP (NN Resveratrol)) (VP (VBZ induces) (NP (NP (NN chemosensitization) (NN 5-fluorouracil) (NN up-regulation) (JJ intercellular) (NN junction)) (, ,) (NP (JJ Epithelial-to-mesenchymal) (NN transition) (NN apoptosis) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 142:I01.880.604 495:G04.299.335.500 560:D03.383.742.698.875.404 1054:A11.284.149.165.420|ES| 2:1 17:1 18:1 19:1 89:1 214:1 552:1 896:1 2307:1 2946:1 3679:1 3680:1 3740:1 3741:1

1 	|BT| (S (S (NP (NP (NN RNA) (NN interference) (JJ knockdown) (NN DRD2) (NN inhibition) (JJ pharmacologic) (NN antagonist)) (PRN (-LRB- -LRB-) (NP (NN pimozide) (NN haloperidol)) (-RRB- -RRB-))) (VP (VBD reduced) (NP (NN proliferation) (JJ pancreatic) (NN cancer) (NN cell)))) (, ,) (VP (VBD induced) (NP (NP (JJ endoplasmic) (NN reticulum) (NN stress) (NN apoptosis)) (, ,) (NP (VBN reduced) (NN cell) (NN migration))))) |ET| |BS|39:G04.299.139.160 43:F01.145.544 156:G05.355.315.203.374.790 183:G04.299.233.750 362:D12.776.543.750.069.300.400.500 681:G04.299.283 1059:H01.158.703 1069:D02.522.352.506 1070:D03.438.103.732 1071:G04.434|ES| 2:1 10:1 14:1 18:1 19:1 89:1 94:1 103:1 299:1 412:1 452:1 464:1 467:1 514:1 515:1 516:1 1210:1 1271:1 2522:1 3742:1 3743:1 3744:1 3745:1 3746:1

1 	|BT| (S (NP (NN Role) (NN microRNA-155) (JJ early) (NN stage) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (JJ choline-deficient) (NN amino) (JJ acid-defined) (NN diet) (NN C57BL/6) (NN mouse)))) |ET| |BS|15:F01.829.316.616 184:D13.150.650.319 593:B01.050.050.199.520.520.420 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125|ES| 19:1 52:1 412:1 900:1 1128:1 1129:1 1957:1 2187:1 2188:1 2189:1 2190:1 2191:1 2192:1

1 	|BT| (NP (NP (NN Role) (JJ transcriptional) (JJ posttranscriptional) (NN regulation) (NN methionine) (NNS adenosyltransferases) (NN liver) (NN cancer) (NN progression))) |ET| |BS|15:F01.829.316.616 16:C23.550.291.656 142:I01.880.604 209:G02.111.087.847 574:D08.811.913.225.650|ES| 18:1 19:1 48:1 438:1 559:1 836:1 1493:1 2050:1 2187:1 3747:1

1 	|BT| (S (NP (NN Roxithromycin)) (VP (VBZ inhibits) (S (NP (NP (JJ constitutive) (NN activation) (JJ nuclear) (NN factor)) (-LRB- -LCB-) (NN kappa) (-RRB- -RCB-) (NN B)) (VP (VBG diminishing) (NP (JJ oxidative) (NN stress) (NN rat) (NN model) (JJ hepatocellular) (NN carcinoma)))))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 104:C04.557.470.200.025.255 122:C14.280.383 210:D12.776.260.600 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 716:G03.495.710 843:D02.540.576.500.992.630|ES| 19:1 72:1 185:1 225:1 303:1 304:1 604:1 615:1 763:1 849:1 1256:1 2522:1 2583:1 3748:1 3749:1 3750:1 3751:1 3752:1

1 	|BT| (NP (NP (JJ Seleno-cyclodextrin) (NNS sensitises) (JJ human) (NN breast) (NN cancer) (NN cell) (JJ TRAIL-induced) (NN apoptosis) (NN DR5) (NN induction) (NN NF-kappaB) (NN suppression))) |ET| |BS|39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 210:D12.776.260.600 1072:D04.345.103|ES| 18:1 19:1 23:1 36:1 89:1 94:1 714:1 736:1 2453:1 3682:1 3753:1 3754:1 3755:1

1 	|BT| (S (NP (NN Selenoprotein) (NN deficiency) (JJ high) (NN level) (NN selenium) (NN compound)) (ADVP (RB effectively)) (VP (VBP inhibit) (NP (NN hepatocarcinogenesis) (JJ transgenic) (NN mouse)))) |ET| |BS|87:C18.654.521 99:B01.050.050.136.500 122:C14.280.383 1073:D12.776.864 1074:D01.810|ES| 19:1 52:1 178:1 249:1 253:1 285:1 900:1 1370:1 2433:1 2977:1 3284:1 3756:1

1 	|BT| (S (NP (NP (NN Signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (VP (VBZ mediates) (NP (NN pathogenesis) (NN colon) (NN cancer) (NN substrate) (NN PTK6)))) |ET| |BS|209:G02.111.087.847 250:E07.305.812|ES| 10:1 14:1 18:1 19:1 113:1 251:1 487:1 501:1 755:1 860:1 861:1 862:1 1041:1 2960:1 3757:1

